Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-777607 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-777607 | DRUG | Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation |
Inclusion Criteria: Part A: * Subjects with advanced or metastatic solid tumors who have either progressed on standard therapy or for whom standard therapy is not known Part B: * Subjects with advanced or metastatic gastroesophageal cancer, HRPrC, HNSCC, or PRCC who have either progressed on sta...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-777607 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is in Phase 1 clinical development and has been evaluated in a completed clinical trial involving patients with advanced or metastatic solid tumors.
BMS-777607 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The drug is currently in Phase 1 clinical development for oncology indications.
BMS-777607 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study of the drug has been completed, but it remains in early-stage clinical testing for advanced solid tumors.
BMS-777607 has been studied in one completed clinical trial, registered as NCT00605618. This was a multiple ascending dose study conducted in Australia with 8 participants who had advanced or metastatic solid tumors. The trial was an uncontrolled, non-randomized, open-label Phase 1 study.
BMS-777607 is the primary name for this investigational drug. No alternative names have been reported for this compound in clinical development. It is being studied under this identifier in the clinical trial registry.